JUUL Is Legal Again — and the FDA's Whole Fix Is a Password Screen

Somewhere in a Truth Initiative dataset is a fact the FDA’s press release doesn’t lead with: most adults who pick up a JUUL were never trying to quit smoking in the first place — they just liked it. That’s the tension sitting underneath the FDA’s August 28 authorization of JUUL2, a redesigned device with an optional app that asks users to prove they’re 21 before it unlocks.

An age-gate app is not a treatment plan. It’s a liability shield with a login screen.

The agency’s own reviewers know the tradeoff they made. So does Dr. Rachel Boykan, who chairs the American Academy of Pediatrics’ nicotine and tobacco section and called the decision “very concerning” days after it landed. What almost nobody outside trade press noticed: the actual pharmaceutical alternative to nicotine addiction, a drug called cytisinicline, got benched by the same agency two months earlier — not for failing patients, but for a factory inspection.

The Deal the FDA Actually Cut

JUUL2 isn’t a new company move. It’s the FDA running its premarket tobacco product application math the way the 2009 Tobacco Control Act built it to run: a product gets a green light only when the agency finds its benefit to the population outweighs its risk — not when it’s proven safe, and not when it’s proven it helps any one person quit. Under that standard, the FDA looked at company data on adult smokers who switched to JUUL2’s tobacco pod and found 19.9% to 34.6% had stopped smoking cigarettes entirely after six weeks; for the menthol pod, that range ran 28.4% to 49.3%. Both pods are dosed at 18 mg/mL — roughly 1.5% to 1.6% nicotine by weight, meaningfully lower than the 5% and 3% pods the FDA tried to pull off shelves in 2022. The agency’s own language on the menthol authorization is blunt about the trade: it decided the product’s “added benefit to adults who smoke cigarettes is sufficient to outweigh the risks of the menthol-flavored product, including youth appeal.”

That’s a real number, and it’s also a number from company-funded switching studies with a six-week window — not an independent trial, and not evidence about who relapses at six months. Cochrane’s pooled analysis of more than 150,000 smokers found nicotine e-cigarettes do help — about 14 of every 100 people quit long-term with one, versus roughly 6 of 100 who try with no aid at all. That’s real, and it’s also a lot less dramatic than “half of users quit in six weeks.”

What Nicotine Does to a Brain That Wants More

Here’s the mechanism, plain first: nicotine hijacks a receptor your brain already uses for normal signaling — the technical name is the nicotinic acetylcholine receptor, specifically a subtype built from α4 and β2 subunits — and forces it to dump dopamine into your reward circuitry faster and harder than it’s built to. Researchers describe it as neurons adapting to expect nicotine’s presence; pull the nicotine away and the same circuitry that made you feel normal now makes you feel like something is missing, because chemically, it is. That’s withdrawal — not weakness, a measurable neuroadaptation.

If you’ve ever put a vape down and made it four hours before your hand found its way back to your pocket anyway, you already understood that mechanism before any of us explained the receptor to you. The dose matters here more than the flavor does: a device that delivers nicotine faster and in a bigger hit trains that circuitry harder, which is exactly why the concentration fight — 18 mg/mL versus JUUL’s old 59 mg/mL, or Zyn pouches’ own climbing potency — isn’t a technicality. It’s the whole mechanism of addiction, in a number on a label.

The Password Is the Whole Policy

JUUL2’s pitch to regulators rests on an optional app: pair the device, verify you’re 21, and it can be “locked” to block use by anyone else. The FDA has now authorized two vaping devices built around this kind of age-gating — a real shift from the flavor-ban era, and also a system that depends entirely on an adult choosing to turn it on, on a device a teenager can still buy, hold, and use unlocked. Boykan’s objection isn’t abstract: “any nicotine, especially in 3%-5% concentration, is highly addictive and dangerous for children and adolescents,” she said, referencing exactly the concentration range JUUL’s earlier, denied products carried — the concentration this new, lower-dose version was designed to move away from, and still didn’t fully escape in public perception.

JUUL2’s pitch to regulators rests on an optional app: pair the device, verify you’re 21, and it can be “locked” to block use by anyone else.

The Company That Wrote the Book on This

Here’s the through-line, because JUUL didn’t arrive at “optional app lock” by accident. The company launched its original device in 2015 and by 2018 had become the product driving what public-health officials would formally call a youth vaping epidemic — a surge so fast the FDA yanked JUUL’s kid-friendly mango, mint, and creme flavors from shelves that same year under direct federal pressure. In 2019, EVALI — a lung-injury outbreak eventually traced mostly to illicit THC vape additives, not nicotine pods — hit while JUUL was already the face of vaping in the public’s mind, and Altria’s $12.8 billion stake in the company was already underwater. By June 2022 the FDA had seen enough: it issued marketing denial orders for every JUUL product on the market, citing insufficient data on toxicology, ordering the company to pull everything. Litigation piled up fast — six states and D.C. won a $462 million settlement in 2023 over marketing to minors, part of roughly $3 billion JUUL has paid out in total. A 19-year-old who wrote into BuzzFeed News back in 2018, describing how she’d picked up her first JUUL during treatment for an eating disorder, put it in words no regulatory filing ever will: she’d disposed of her device in the Hudson River and leaned on friends who were quitting alongside her, because nothing about walking away from it was easy. The FDA rescinded its own 2022 ban in 2024, citing new case law, without declaring JUUL’s products safe or effective — just un-banned. JUUL2 is what came out the other side of that decade.

The Actual Medicine Is Stuck in a Manufacturing Queue

While regulators were weighing app-lock e-cigarettes, the pharmaceutical answer to nicotine addiction was sitting in a different inbox. Cytisinicline — a plant-derived compound that works on the same nicotinic receptors nicotine does, but more gently, easing withdrawal while blunting nicotine’s reward — would have been the first new FDA-approved smoking-cessation drug since varenicline in 2006, backed by two positive Phase 3 trials. On June 22, 2026, the FDA sent Achieve Life Sciences a rejection letter — technically a Complete Response Letter, regulatory shorthand for “not yet” — not because the drug didn’t work, but over failed factory-inspection standards (cGMP, the FDA’s manufacturing rulebook) at a third-party plant, plus incomplete labeling. The company’s own release is explicit: “The FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline,” CEO Andrew Goldberg said, with a resubmission targeted for the fourth quarter of 2026 and possible approval in the first half of 2027.

So if you’re trying to quit nicotine tonight, the newest tool with real trial data behind it isn’t on shelves yet, and won’t be for months. What is on shelves, covered by most insurance and available over the counter without a wait: nicotine patches and gum, varenicline by prescription, and — per that same Cochrane analysis — combining approaches beats going it alone. A 2026 meta-analysis in Addiction found pairing varenicline with nicotine replacement therapy significantly outperforms either one by itself. None of that is a lock screen. It’s a prescription, a patch, and — per every trial on the subject — someone checking in with you while you do it.

JUUL’s app can ask your age. It can’t ask why you started, and it isn’t built to help you stop. The receptor doesn’t check IDs.